Nytricx Management
Ronald Shebuski
PhD, Founder, President and CEO
Dr. Shebuski is highly experienced pharmacologist with a broad drug development background in large pharma and cardiovascular biotech start-ups. Before directing the Cardiovascular Therapeutics group at Pharmacia & Upjohn, Dr. Shebuski was a Senior Scientist responsible for leading cardiovascular drug discovery teams at Merck and Smith Kline & French Laboratories.
Hitesh Handa
PhD, Founder and Chief Scientific Officer
Dr. Handa is a Professor in the College of Engineering at the University of Georgia-Athens with over ten years industrial and academic experience in nitric oxide (NO)-releasing materials, surface science, coating development, antibacterial and hemocompatible materials and small animal models. Nytricx novel technology is based on work from his laboratory (over 50 NO-related publications) on development of NO-releasing surfaces that function as anti-thrombotic and anti-microbial platforms.
Elizabeth Brisbois
PhD, Founder and Chief Technical Officer
Dr. Brisbois is an Associate Professor in the College of Engineering at the UGA-Athens, with over ten years of background and technical experience in analytical/materials chemistry. Dr. Brisbois has expertise in biomedical engineering, specifically in the field of nitric oxide (NO)-releasing biomaterials for biocompatible medical device applications, and has numerous publications, patents and research funding from NIH, JDRF, and CDC.
Patrick Delehanty
MBA, Founder, Chief Operations Officer and Chief Financial Officer
